Tuberculosis (TB) remains a significant public health concern in Kenya, with the World Health Organization (WHO) reporting an incidence rate of 522 per 100,000 population in 2020. To combat this, the Kenyan Ministry of Health (MOH) has implemented robust treatment guidelines, aligned with international standards. Let's delve into the current TB treatment guidelines in Kenya.

These guidelines, last updated in 2021, aim to ensure standardized, effective, and patient-centered care. They cover all forms of TB, including pulmonary, extra-pulmonary, latent, and drug-resistant TB. Here, we'll explore the key aspects of these guidelines, focusing on new and retreatment cases, as well as drug-resistant TB.

New and Retreatment Cases
The treatment of new and retreatment cases of TB in Kenya follows a standardized regimen, with some variations based on the patient's history and disease presentation.

For new cases, the recommended regimen is a 6-month course consisting of 2 months of intensive phase (Isoniazid, Rifampicin, Pyrazinamide, and Ethambutol) followed by 4 months of continuation phase (Isoniazid and Rifampicin).
Directly Observed Therapy (DOT)

Kenya emphasizes DOT for new cases, especially in the intensive phase. This involves a health worker observing the patient taking their medication, ensuring adherence and minimizing the risk of treatment failure and drug resistance.
For retreatment cases, the guidelines recommend a 9-month course, with the first 2 months being the same as the intensive phase for new cases. The continuation phase varies, with Ethambutol and Streptomycin added to the regimen to prevent relapse and treatment failure.
Treatment of Extra-pulmonary TB

Extra-pulmonary TB (EPTB) accounts for about 20% of TB cases in Kenya. The treatment of EPTB mirrors that of pulmonary TB, with some adjustments based on the affected site and severity of disease. For instance, TB meningitis may require a longer treatment duration and the addition of steroids to manage inflammation.
Surgical intervention may also be considered in some EPTB cases, such as spinal TB, to decompress the spine and prevent neurological damage. The decision to operate is based on the patient's clinical presentation, radiological findings, and response to medical treatment.
Drug-Resistant TB

Kenya has a high burden of drug-resistant TB (DR-TB), with an estimated 2.7% of new TB cases and 12% of retreatment cases being rifampicin-resistant or multidrug-resistant (MDR-TB). The treatment of DR-TB is complex and prolonged, requiring a combination of second-line drugs.
The national guidelines recommend a 9-20 month regimen for MDR-TB, depending on the patient's drug susceptibility profile. The regimen includes a combination of injectable drugs (Amikacin, Capreomycin, or Streptomycin) and oral drugs (Fluoroquinolones, Ethionamide, Cycloserine, and Pyrazinamide). The use of bedaquiline and delamanid, newer drugs for MDR-TB, is also recommended in certain scenarios.




















Bedaquiline and Delamanid Programmatic Management
Kenya was one of the first countries to introduce bedaquiline and delamanid, the first new TB drugs in over 40 years. These drugs have significantly improved the treatment outcomes for MDR-TB patients. The Kenyan MOH has developed a programmatic management guide for these drugs, outlining their use, monitoring, and safety considerations.
The guidelines also emphasize the importance of infection prevention and control measures, especially in healthcare facilities, to prevent the transmission of TB and drug-resistant strains. This includes early diagnosis, proper use of personal protective equipment, and adequate ventilation.
In conclusion, Kenya's TB treatment guidelines reflect a comprehensive and robust approach to managing TB, from new and retreatment cases to drug-resistant TB. They emphasize standardized care, patient-centeredness, and the use of evidence-based practices. As we look to the future, continued efforts to improve TB diagnosis, treatment, and prevention will be crucial to ending this epidemic in Kenya.